APOE and Alzheimer disease: There were significant dose-dependent reductions in PET-imaged amyloid in all affected brain regions after 54 weeks in the 3–10 mg/kg groups, with no differences between prodromal and mild AD, or between APOE4 carriers and non-carriers.